Treatment of Psoriasis With Depression and/or Anxiety With Methotrexate vs Combined Methotrexate and Antidepressant

Condition(s) studied

Investigational drug(s) / intervention(s)

Combination of methotrexate and escitalopram in treatment of psoriasis patients with depression and/or anxiety: Combination of methotrexate and escitalopram in treatment of psoriasis patients with depression and/or anxiety

Methotrexate: Methotrexate 0.4mg/kg once weekly for 6 months

Study summary

This randomized controlled trial aims to compare the efficacy of methotrexate (MTX) monotherapy versus combined methotrexate and selective serotonin reuptake inhibitor (SSRI) therapy in patients with psoriasis and comorbid depression and/or anxiety. Participants will be randomly assigned to two groups: one receiving MTX alone and the other receiving MTX plus escitalopram. Clinical outcomes will be evaluated over a 6-month period, including psoriasis severity using the Psoriasis Area and Severity Index (PASI) and Body Surface Area (BSA), quality of life using the Dermatology Life Quality Index (DLQI), and psychological status using the Beck Depression Inventory (BDI), Beck Anxiety Inventory (BAI), Hamilton Depression Rating Scale (HAM-D), and Hamilton Anxiety Rating Scale (HAM-A). The study will assess whether combination therapy provides superior clinical and psychological outcomes.

Eligibility

Primary outcome measure(s)

• comparison of Percentage change in PASI score from baseline to 6 months between group A and B — 6 months
• Comparison between percentage change of BDI, BAI, Ham-A and Ham-D in groups A&B — 6 months
• Comparison of percentage of patients who achieved PASI 75%, 90% & 100% between groups A & B — 6 months

Trial sites (1)

More Cairo University trials in Egypt

Other trials for the same condition